JP2008534017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534017A5 JP2008534017A5 JP2008504393A JP2008504393A JP2008534017A5 JP 2008534017 A5 JP2008534017 A5 JP 2008534017A5 JP 2008504393 A JP2008504393 A JP 2008504393A JP 2008504393 A JP2008504393 A JP 2008504393A JP 2008534017 A5 JP2008534017 A5 JP 2008534017A5
- Authority
- JP
- Japan
- Prior art keywords
- dkkl
- antibody
- splice product
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 27
- 108010029485 Protein Isoforms Proteins 0.000 claims 22
- 102000001708 Protein Isoforms Human genes 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 15
- 230000014509 gene expression Effects 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 10
- 102000013814 Wnt Human genes 0.000 claims 5
- 108050003627 Wnt Proteins 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 239000012216 imaging agent Substances 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 201000009613 breast lymphoma Diseases 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000099 in vitro assay Methods 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 201000003714 breast lobular carcinoma Diseases 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66643105P | 2005-03-30 | 2005-03-30 | |
| PCT/US2006/011761 WO2006105343A2 (en) | 2005-03-30 | 2006-03-30 | Dkkl-i splice product modulators for cancer diagnosis and therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534017A JP2008534017A (ja) | 2008-08-28 |
| JP2008534017A5 true JP2008534017A5 (enExample) | 2009-03-19 |
Family
ID=36950360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504393A Pending JP2008534017A (ja) | 2005-03-30 | 2006-03-30 | 癌の診断および治療のためのｄｋｋｌ−１のスプライス産物の調節因子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8252267B2 (enExample) |
| EP (1) | EP1896495A2 (enExample) |
| JP (1) | JP2008534017A (enExample) |
| WO (1) | WO2006105343A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| EP3488019B1 (en) * | 2016-07-21 | 2025-02-12 | The General Hospital Corporation | Extracellular mrna markers of muscular dystrophies in human urine |
| CN110178184B (zh) * | 2017-01-17 | 2024-04-19 | Illumina公司 | 致癌剪接变体确定 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736120A (en) * | 1996-06-07 | 1998-04-07 | Srinivasan; Ananthachari | Method for preparing radiolabeled peptides |
| WO1999066041A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| US7057017B2 (en) * | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| DE69841110D1 (de) * | 1997-12-17 | 2009-10-08 | Serono Genetics Inst Sa | Verlängerte cdns, die für sekretierte proteine kodieren |
| WO2000052047A2 (en) * | 1999-03-05 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| AU2002359579A1 (en) | 2001-12-05 | 2003-06-23 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2003248933A1 (en) | 2002-07-11 | 2004-02-02 | Incyte Corporation | Secreted proteins |
| EP1678325A2 (en) * | 2003-09-30 | 2006-07-12 | Chiron Corporation | Novel splice variants of human dkkl1 |
-
2006
- 2006-03-30 US US11/887,692 patent/US8252267B2/en not_active Expired - Fee Related
- 2006-03-30 WO PCT/US2006/011761 patent/WO2006105343A2/en not_active Ceased
- 2006-03-30 EP EP06740112A patent/EP1896495A2/en not_active Withdrawn
- 2006-03-30 JP JP2008504393A patent/JP2008534017A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jie et al. | CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification | |
| Jiao et al. | VGLL4 targets a TCF4–TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer | |
| Morrison et al. | Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer | |
| Li et al. | TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation | |
| US12286484B2 (en) | Targeting metastasis stem cells through a fatty acid receptor (CD36) | |
| Aryee et al. | Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro | |
| US7776541B2 (en) | Psoriasin expression by breast epithelial cells | |
| Li et al. | Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines | |
| CN103328500B (zh) | 用于癌症的诊断和治疗的方法和化合物 | |
| Gao et al. | Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-κB signaling pathway | |
| MX2008007650A (es) | Metodo para diagnostico, pronostico y tratamiento de glioma. | |
| Shu et al. | Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma | |
| EP3436601B1 (en) | Cytidine deaminase expression level in cancer as a new therapeutic target | |
| CN112512577A (zh) | 结直肠癌的治疗、预防和预后检测的方法 | |
| Dmitrenko et al. | Reduction of the transcription level of the mitochondrial genome in human glioblastoma | |
| Huerta et al. | Mechanisms of resistance to ionizing radiation in rectal cancer | |
| KR20180109811A (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| JP2005520543A5 (enExample) | ||
| Xu et al. | Exosome-transported circHDAC1_004 promotes proliferation, migration, and angiogenesis of hepatocellular carcinoma by the miR-361-3p/NACC1 axis | |
| JP2008534017A5 (enExample) | ||
| CN114058700A (zh) | Rbm10基因的用途 | |
| KR101495275B1 (ko) | 폐암 진단 및 치료를 위한 표적 단백질 | |
| Zhao et al. | Nerve Growth Factor Signaling Promotes Nuclear Translocation of TRAF4 to Enhance Tumor Stemness and Metastatic Dormancy Via C‐Jun‐mediated IL‐8 Autocrine | |
| JP2008535854A5 (enExample) | ||
| KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 |